| ADT | Androgen Deprivation Therapy |
| AE | Adverse Events |
| ARPI | Androgen Receptor Pathway Inhibitor |
| BC | Biochemical Control |
| BFS | Biochemical Failure-free Survival |
| CBCT | Cone-Beam Computed Tomography |
| CRPC | Castration-Resistant Prostate Cancer |
| CTCAE | Common Terminology Criteria for Adverse Events |
| CTV | Clinical Target Volume |
| ECOG | Eastern Cooperative Oncology Group performance status |
| EBRT | External Beam Radiation Therapy |
| G | Grade |
| HSPC | Hormone-Sensitive Prostate Cancer |
| LC | Local Control |
| MFS | Metastasis-Free Survival |
| mpMRI | Multiparametric Magnetic Resonance Imaging |
| MDT | Metastasis-Directed Therapies |
| OS | Overall Survival |
| PSMA-PET | Prostate-Specific Membrane Antigen Positron Emission Tomography |
| PTV | Planning Target Volume |
| RFS | Relapse-Free Survival |
| RP | Post-operative Radiotherapy |
| s-SBRT | Salvage Stereotactic Body Radiation Therapy |